CLLS vs. IVA, PHAT, AURA, TRDA, TKNO, OLMA, CMPX, RCKT, HRTX, and ACB
Should you be buying Cellectis stock or one of its competitors? The main competitors of Cellectis include Inventiva (IVA), Phathom Pharmaceuticals (PHAT), Aura Biosciences (AURA), Entrada Therapeutics (TRDA), Alpha Teknova (TKNO), Olema Pharmaceuticals (OLMA), Compass Therapeutics (CMPX), Rocket Pharmaceuticals (RCKT), Heron Therapeutics (HRTX), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry.
Cellectis vs.
Inventiva (NASDAQ:IVA) and Cellectis (NASDAQ:CLLS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, community ranking, institutional ownership and dividends.
In the previous week, Inventiva had 3 more articles in the media than Cellectis. MarketBeat recorded 5 mentions for Inventiva and 2 mentions for Cellectis. Cellectis' average media sentiment score of 1.84 beat Inventiva's score of 1.20 indicating that Cellectis is being referred to more favorably in the news media.
Inventiva has a net margin of 0.00% compared to Cellectis' net margin of -234.39%. Inventiva's return on equity of 0.00% beat Cellectis' return on equity.
Inventiva presently has a consensus target price of $10.40, suggesting a potential upside of 184.93%. Cellectis has a consensus target price of $7.00, suggesting a potential upside of 396.45%. Given Cellectis' stronger consensus rating and higher possible upside, analysts clearly believe Cellectis is more favorable than Inventiva.
Cellectis received 391 more outperform votes than Inventiva when rated by MarketBeat users. However, 82.76% of users gave Inventiva an outperform vote while only 64.95% of users gave Cellectis an outperform vote.
Cellectis has higher revenue and earnings than Inventiva.
Inventiva has a beta of 0.75, indicating that its share price is 25% less volatile than the S&P 500. Comparatively, Cellectis has a beta of 2.92, indicating that its share price is 192% more volatile than the S&P 500.
19.1% of Inventiva shares are owned by institutional investors. Comparatively, 63.9% of Cellectis shares are owned by institutional investors. 32.0% of Inventiva shares are owned by insiders. Comparatively, 16.4% of Cellectis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Summary
Inventiva and Cellectis tied by winning 8 of the 16 factors compared between the two stocks.
Get Cellectis News Delivered to You Automatically
Sign up to receive the latest news and ratings for CLLS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cellectis Competitors List
Related Companies and Tools
This page (NASDAQ:CLLS) was last updated on 6/11/2025 by MarketBeat.com Staff
Buy CLLS Stock Free CLLS Stock Alerts